The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2009The Effect of 4-hydroxy-2-nonenal Modification on Alpha-synuclein Toxicity
Objective/Rationale:
Alpha-synuclein is a protein that is normally produced in the human brain. Compelling evidence suggests that alpha-synuclein can acquire a toxic feature that kills dopamine... -
Rapid Response Innovation Awards, 2009Aldehyde Dehydrogenase Activators as Novel Drugs For the Treatment of PD
Objective/Rationale:
The accumulation of at least two toxic products in the brain called DOPAL and 4HNE results in death of neurons that are implicated in Parkinson’s Disease (PD). We identified a... -
Rapid Response Innovation Awards, 2009Enzymes that Catalyze for Alpha-synuclein Ubiquitination and Degradation
Objective/Rationale:
A characteristic feature of Parkinson’s disease (PD) is the buildup of the protein, alpha-synuclein, and overproduction of this protein can trigger PD. Therefore, it is important... -
Rapid Response Innovation Awards, 2009Serum Biomarkers for Parkinson's Disease
Objective/Rationale:
The immune system appears to play an important role in the progression of Parkinson’s disease, and immunotherapy may offer an approach to slow or stop disease progression. The... -
Rapid Response Innovation Awards, 2009Small Molecule Inhibitors of Alpha-synuclein Assembly and Toxicity
Objective/Rationale:
We will test a novel drug candidate that blocks formation of the toxic aggregates of the protein alpha-synuclein, which are believed to cause Parkinson’s disease (PD). Our drug... -
Rapid Response Innovation Awards, 2009Glycine Uptake Inhibitors as Potential Enhancers of Dopaminergic Axon Regeneration
Objective/Rationale
An important goal in Parkinson’s disease therapy is to restore the loss of the dopaminergic innervation of the striatum. Cell culture data from our lab indicate that activation of...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.